

Appendix 4. Included Study Characteristics and Effect Modifiers

Study Identifier	Comparison	Sample size	Previous CS	Parity	Membranes	Cervix	Gestational age	No. Foetuses	Risk of Bias	Setting	Financial Disclosure
Adair 1998	Vaginal misoprostol (Dose 50 mcg or more) vs Oral misoprostol tablet (dose 50mcg or more)	178	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Adam 2005	Vaginal misoprostol (Dose 50 mcg or more) vs Oral misoprostol tablet (dose 50mcg or more)	80	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	Not reported/ not clear	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Agarwal 2003	Intracervical PGE2 vs Vaginal misoprostol (Dose 50 mcg or more)	120	None with previous CS	Mixed parity	All intact	All favourable (>6)	Mixed (includes preterm)	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Al-Malt 1995	Placebo vs Vaginal PGE2 (gel)	103	Not reported/ not clear	Not reported/ not clear	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Not reported/ not clear.	Not reported/ not clear.
Al-Sebai 1992	Vaginal PGE2 (tablet) vs Vaginal PGE2 (gel)	73	None with previous CS	Nulliparous only	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Not reported/ not clear.	Not reported/ not clear.
Anand 2012	Intracervical PGE2 vs Vaginal misoprostol (Dose less than 50 mcg)	200	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Ayad 2002	Intracervical PGE2 vs Vaginal misoprostol (Dose 50 mcg or more)	238	None with previous CS	Mixed parity	All ruptured	Mixed	Mixed (includes preterm)	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Ayaz 2008	No treatment vs Oral misoprostol tablet (dose 50mcg or more)	84	None with previous CS	Multiparous only	All ruptured	Not reported/ not clear	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Ayaz 2010	Vaginal PGE2 (tablet) vs Vaginal misoprostol (Dose 50 mcg or more)	120	None with previous CS	Nulliparous only	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Bartha 2000	Intracervical PGE2 vs Oral misoprostol tablet (dose 50mcg or more)	200	Some with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Beigi 2003	Placebo vs Oral misoprostol tablet (dose 50mcg or more)	156	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.

Bennett 1998	Vaginal misoprostol (Dose 50 mcg or more) vs Oral misoprostol tablet (dose 50mcg or more)	206	None with previous CS	Mixed parity	All intact	Mixed	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Bernstein 1991	Placebo vs Intracervical PGE2	397	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	Some or all funding from pharmaceutical industry
Berzircioglu 2012	No treatment vs Vaginal PGE2 (pessary - slow release)	100	None with previous CS	Mixed parity	All ruptured	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Bounyasong 2000	Vaginal misoprostol (Dose less than 50 mcg) vs Vaginal misoprostol (Dose 50 mcg or more)	166	None with previous CS	Mixed parity	All intact	Not reported/ not clear	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Buchanan 1984	Placebo vs Vaginal PGE2 pessary (normal release)	77	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	Mixed (includes preterm)	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Buser 1997	Intracervical PGE2 vs Vaginal misoprostol (Dose 50 mcg or more)	155	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Buttino 1990	Placebo vs Intracervical PGE2	43	Not reported/ not clear	Not reported/ not clear	Not reported/ not clear	Not reported/ not clear	All post-term	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	One or both arms outpatient.	Not reported/ not clear.
Cabrol 1988	Placebo vs Intracervical PGE2	217	Not reported/ not clear	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Campbell 1984	Placebo vs Vaginal PGE2 pessary (normal release) vs	199	Not reported/ not clear	Mixed parity	Mixed	Mixed	Mixed (includes preterm)	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Cararach 1996	No treatment vs Intracervical PGE2	341	Not reported/ not clear	Not reported/ not clear	All ruptured	All unfavourable (<6)	Mixed (includes preterm)	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest

Cardozo 1986	No treatment vs Vaginal PGE2 pessary (normal release)	402	Not reported/ not clear	Not reported/ not clear	All intact	Mixed	All post-term	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Carlan 2001	Vaginal misoprostol (Dose 50 mcg or more) vs Oral misoprostol tablet (dose 50mcg or more)	1004	Some with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Chang 1997 9474	Vaginal PGE2 (tablet) vs Vaginal misoprostol (Dose 50 mcg or more)	60	None with previous CS	Nulliparous only	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Charoenkul 2000	Vaginal PGE2 (tablet) vs Vaginal misoprostol (Dose 50 mcg or more)	143	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Chatterjee 1990	Placebo vs Vaginal PGE2 (gel)	33	Not reported/ not clear	Mixed parity	Not reported/ not clear	All unfavourable (<6)	Mixed (includes preterm)	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Chaudhuri 2011	Vaginal PGE2 (gel) vs Vaginal misoprostol (Dose less than 50 mcg)	207	None with previous CS	Mixed parity	All ruptured	Mixed	All > 37 weeks	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Cheng 2008	Vaginal misoprostol (Dose less than 50 mcg) vs Titrated (low dose) oral misoprostol solution	207	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Cheung 2006	Placebo vs Oral misoprostol tablet (dose 50mcg or more)	98	None with previous CS	Nulliparous only	All ruptured	Mixed	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Chitraker 2012	Intracervical PGE2 vs Vaginal misoprostol (Dose less than 50 mcg)	200	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Chua 1995	Placebo vs Vaginal PGE2 pessary (normal release)	155	None with previous CS	Nulliparous only	All ruptured	All unfavourable (<6)	All > 37 weeks	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.

Chuck 1995	Intracervical PGE2 vs Vaginal misoprostol (Dose 50 mcg or more)	99	Some with previous CS	Mixed parity	Mixed	Mixed	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Chung 1992	Placebo vs Vaginal PGE2 (gel)	59	Not reported/ not clear	Mixed parity	All ruptured	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Chyu 1997	Vaginal PGE2 (pessary - slow release) vs Intracervical PGE2	73	Not reported/ not clear	Mixed parity	Mixed	Mixed	Not reported/ not clear	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Clark 1998	Intracervical PGE2 vs Vaginal misoprostol (Dose less than 50 mcg)	138	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	Not reported/ not clear	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Colon 2005	Vaginal misoprostol (Dose less than 50 mcg) vs Oral misoprostol tablet (dose 50mcg or more)	204	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	Mixed (includes preterm)	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Corrado 2001	Vaginal PGE2 (gel) vs Intracervical PGE2	233	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Curet 1989	Placebo vs Vaginal PGE2 (gel)	54	Not reported/ not clear	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Da Graca 2005	No treatment vs Vaginal misoprostol (Dose less than 50 mcg)	150	None with previous CS	Mixed parity	All ruptured	Not reported/ not clear	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Dallenbach 2003	Vaginal PGE2 (gel) vs Oral misoprostol tablet (Dose less than 50 mcg)	200	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Danielian 1999	Vaginal PGE2 (gel) vs Vaginal misoprostol (Dose 50 mcg or more)	211	Some with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Darroca 1996	Placebo vs Intracervical PGE2	118	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	Mixed (includes preterm)	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	One or both arms outpatient.	Not reported/ not clear.

Deng 1999	Placebo vs Vaginal misoprostol (Dose 50 mcg or more)	85	Not reported/ not clear	Not reported/ not clear	Not reported/ not clear	All unfavourable (<6)	Not reported/ not clear	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Denguezli 2007	Intracervical PGE2 vs Vaginal misoprostol (Dose 50 mcg or more) vs Mechanical methods - foley catheter	130	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Deo 2012	Vaginal PGE2 (gel) vs Vaginal misoprostol (Dose less than 50 mcg) vs Mechanical methods - foley catheter	158	Not reported/ not clear	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Diro 1999	Vaginal misoprostol (Dose less than 50 mcg) vs Vaginal misoprostol (Dose 50 mcg or more)	251	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Doany 1997	Placebo vs Vaginal PGE2 (gel) vs Membrane sweeping	115	None with previous CS	Mixed parity	All intact	Mixed	All post-term	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Dodd 2006	Vaginal PGE2 (gel) vs Titrated (low dose) oral misoprostol solution	741	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Domisse 1980	Placebo vs Vaginal PGE2 (tablet)	56	Not reported/ not clear	Mixed parity	All intact	All favourable (>6)	Mixed (includes preterm)	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Dyar 2000	Vaginal misoprostol (Dose 50 mcg or more) vs Oral misoprostol tablet (dose 50mcg or more)	153	None with previous CS	Not reported/ not clear	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Egarter 1989	No treatment vs Vaginal PGE2 (tablet)	345	None with previous CS	Mixed parity	All intact	Mixed	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	One or both arms outpatient.	Not reported/ not clear.

Ekman 1983	Vaginal PGE2 (gel) vs Intracervical PGE2	60	Not reported/ not clear	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
El-Din 2000	Vaginal PGE2 (tablet) vs Intracervical PGE2 vs Vaginal misoprostol (Dose 50 mcg or more)	149	Not reported/ not clear	Not reported/ not clear	Not reported/ not clear	All unfavourable (<6)	Not reported/ not clear	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Elhassan 2004	Vaginal PGE2 (tablet) vs Vaginal misoprostol (Dose 50 mcg or more)	120	None with previous CS	Mixed parity	Not reported/ not clear	Not reported/ not clear	Not reported/ not clear	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Elhassan 2005	Vaginal misoprostol (Dose less than 50 mcg) vs Vaginal misoprostol (Dose 50 mcg or more)	63	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	Not reported/ not clear	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Elhassan 2007	Vaginal misoprostol (Dose 50 mcg or more) vs Oral misoprostol tablet (dose 50mcg or more) vs Buccal/sublingual misoprostol	150	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	Not reported/ not clear	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
El-Mardi 1991	Vaginal PGE2 (tablet) vs Vaginal PGE2 pessary (normal release)	200	Not reported/ not clear	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
El-Shawarby 2006	Vaginal PGE2 (gel) vs Vaginal PGE2 (pessary - slow release)	72	Not reported/ not clear	Mixed parity	Mixed	Mixed	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
El-Sherbiny 2001	Vaginal misoprostol (Dose less than 50 mcg) vs Vaginal misoprostol (Dose 50 mcg or more)	185	None with previous CS	Mixed parity	All intact	Mixed	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Eroglu 2007	Vaginal misoprostol (Dose less than 50 mcg) vs Vaginal misoprostol (Dose 50 mcg or more)	147	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Facchinetti 2005	Vaginal PGE2 (pessary - slow release) vs Intracervical PGE2	144	None with previous CS	Nulliparous only	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Fachinetti 2007	Vaginal PGE2 (pessary - slow release) vs Intracervical PGE2	116	None with previous CS	Nulliparous only	All intact	All unfavourable (<6)	All post-term	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.

Farah 1997	Vaginal misoprostol (Dose less than 50 mcg) vs Vaginal misoprostol (Dose 50 mcg or more)	399	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Ferraiolo 2010	Vaginal PGE2 (gel) vs Vaginal PGE2 (pessary - slow release)	144	None with previous CS	Nulliparous only	All intact	All unfavourable (<6)	All > 37 weeks	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Fisher 2001	Vaginal misoprostol (Dose 50 mcg or more) vs Oral misoprostol tablet (dose 50mcg or more)	126	None with previous CS	Mixed parity	All intact	Mixed	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Fletcher 1993	Placebo vs Vaginal misoprostol (Dose 50 mcg or more)	45	Not reported/ not clear	Mixed parity	Not reported/ not clear	Not reported/ not clear	Mixed (includes preterm)	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Fletcher 1994	Vaginal PGE2 (tablet) vs Vaginal misoprostol (Dose 50 mcg or more)	63	None with previous CS	Mixed parity	All intact	Mixed	Not reported/ not clear	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Frass 2011	No treatment vs Vaginal misoprostol (Dose 50 mcg or more)	113	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Frohn 2002	Vaginal PGE2 (gel) vs Vaginal misoprostol (Dose 50 mcg or more)	109	Some with previous CS	Mixed parity	All ruptured	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Garry 2003	Vaginal PGE2 (pessary - slow release) vs Vaginal misoprostol (Dose 50 mcg or more)	186	Some with previous CS	Mixed parity	Mixed	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Gelisen 2005	No treatment vs Vaginal misoprostol (Dose 50 mcg or more) vs IV oxytocin vs Mechanical methods - foley catheter	600	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All post-term	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Getgan 2003	Vaginal misoprostol (Dose less than 50 mcg) vs Oral misoprostol tablet (dose 50mcg or more)	72	Not reported/ not clear	Not reported/ not clear	All intact	All unfavourable (<6)	Not reported/ not clear	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.

Gherman 2001	Vaginal PGE2 (gel) vs Oral misoprostol tablet (dose 50mcg or more)	58	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Gilson 1993	Placebo vs Intracervical PGE2	79	Some with previous CS	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	One or both arms outpatient.	No pharmaceutical industry funding/ no conflicts of interest
Girija 2009	Vaginal misoprostol (Dose less than 50 mcg) vs Vaginal misoprostol (Dose 50 mcg or more)	100	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Girija 2011	Intracervical PGE2 vs Vaginal misoprostol (Dose less than 50 mcg)	320	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Gittens 1996	No treatment vs Intracervical PGE2	32	All with previous CS	Not reported/ not clear	All intact	All unfavourable (<6)	All > 37 weeks	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	One or both arms outpatient.	Not reported/ not clear.
Gottschall 2007	Vaginal PGE2 (gel) vs Vaginal misoprostol (Dose 50 mcg or more)	75	None with previous CS	Mixed parity	All intact	Not reported/ not clear	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Graves 1985	Placebo vs Vaginal PGE2 (gel)	80	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	Not reported/ not clear	Singleton	Report describes allocation concealment. Low risk of bias. No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Some or all funding from pharmaceutical industry
Green 1998	Vaginal PGE2 (gel) vs Vaginal PGE2 (pessary - slow release)	107	Not reported/ not clear	Mixed parity	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Greer 1990	Vaginal PGE2 (tablet) vs Vaginal PGE2 (gel)	24	Not reported/ not clear	Multiparous only	Not reported/ not clear	Mixed	All > 37 weeks	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Gregson 2005	Vaginal PGE2 (gel) vs Vaginal misoprostol (Dose less than 50 mcg)	268	None with previous CS	Mixed parity	Mixed	Mixed	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.

Grunberger 1986	Placebo vs Intracervical PGE2	30	None with previous CS	Not reported/ not clear	Not reported/ not clear	All unfavourable (<6)	All post-term	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Gupta 2010	Vaginal misoprostol (Dose less than 50 mcg) vs Vaginal misoprostol (Dose 50 mcg or more)	148	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Mixed	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Hales 1994	Vaginal PGE2 (gel) vs Intracervical PGE2	100	Not reported/ not clear	Not reported/ not clear	All intact	All unfavourable (<6)	All > 37 weeks	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Hall 2002	Vaginal misoprostol (Dose less than 50 mcg) vs Oral misoprostol tablet (dose 50mcg or more)	107	None with previous CS	Mixed parity	Mixed	Not reported/ not clear	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Hannah 1996	No treatment vs Vaginal PGE2 (gel)	2520	Some with previous CS	Mixed parity	All ruptured	Not reported/ not clear	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	One or both arms outpatient.	No pharmaceutical industry funding/ no conflicts of interest
Has 2002	Vaginal misoprostol (Dose less than 50 mcg) vs Vaginal misoprostol (Dose 50 mcg or more)	114	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Hayashi 1983	Placebo vs Vaginal PGE2 (gel)	60	Not reported/ not clear	Mixed parity	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	Some or all funding from pharmaceutical industry
Heinzl 1980	Placebo vs Intracervical PGE2	120	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Henrich 2008	Vaginal PGE2 (gel) vs Oral misoprostol tablet (dose 50mcg or more)	224	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Herabutya 1992	No treatment vs Intracervical PGE2	108	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All post-term	Singleton	No description of allocation concealment or unclear description. High risk of bias.	One or both arms outpatient.	Not reported/ not clear.

Herabutya 1993	Vaginal PGE2 (tablet) vs Intracervical PGE2	48	Not reported/ not clear	Nulliparous only	All intact	All unfavourable (<6)	Not reported/ not clear	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	One or both arms outpatient.	Not reported/ not clear.
Herabutya 1997	Intracervical PGE2 vs Vaginal misoprostol (Dose 50 mcg or more)	110	Not reported/ not clear	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Hidar 2000	No treatment vs Intracervical PGE2	88	None with previous CS	Mixed parity	All ruptured	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Hoffman 2001	Placebo vs Oral misoprostol tablet (dose 50mcg or more) Vaginal PGE2 (gel) vs Titrated (low dose) oral misoprostol solution vs Mechanical methods - foley catheter	96	None with previous CS	Mixed parity	All ruptured	Not reported/ not clear	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Hofmeyr 2001		866	None with previous CS	Mixed parity	Mixed	Mixed	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Hosli 2008	Vaginal PGE2 (gel) vs Vaginal misoprostol (Dose 50 mcg or more)	107	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
How 2001	Vaginal misoprostol (Dose less than 50 mcg) vs Oral misoprostol tablet (Dose less than 50 mcg)	219	Some with previous CS	Mixed parity	All ruptured	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Howarth 1996	Vaginal PGE2 (gel) vs Vaginal misoprostol (Dose 50 mcg or more)	72	None with previous CS	Mixed parity	All intact	Mixed	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Husslein 1986	No treatment vs Vaginal PGE2 (tablet)	345	None with previous CS	Mixed parity	All intact	All favourable (>6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Hutcheon 1980	Placebo vs Intracervical PGE2	67	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	Not reported/ not clear	Singleton	Report describes allocation concealment. Low risk of bias.	One or both arms outpatient.	No pharmaceutical industry funding/ no conflicts of interest

Incerpi 2001	Placebo vs Vaginal misoprostol (Dose less than 50 mcg)	120	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias. No description of allocation concealment or unclear description. High risk of bias.	One or both arms outpatient.	Not reported/ not clear.
Irion 1998	Vaginal PGE2 (gel) vs Intracervical PGE2	247	Some with previous CS	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias. No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Jindal 2011	Vaginal misoprostol (Dose 50 mcg or more) vs Oral misoprostol tablet (dose 50mcg or more)	103	None with previous CS	Mixed parity	All ruptured	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Some or all funding from pharmaceutical industry
Kadanali 1996	Intracervical PGE2 vs Vaginal misoprostol (Dose 50 mcg or more)	224	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Kalkat 2008	Vaginal PGE2 (gel) vs Vaginal PGE2 (pessary - slow release)	120	None with previous CS	Mixed parity	Not reported/ not clear	Mixed	Mixed (includes preterm)	Mixed	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Keirse 1995	Vaginal PGE2 (gel) vs Intracervical PGE2	282	None with previous CS	Mixed parity	All intact	Mixed	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias. No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Kemp 2000	Vaginal PGE2 (gel) vs Intracervical PGE2	470	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	Mixed (includes preterm)	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Khazardoost 2011	Vaginal misoprostol (Dose less than 50 mcg) vs Oral misoprostol tablet (dose 50mcg or more)	60	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All post-term	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Khoury 2001	Vaginal PGE2 (pessary - slow release) vs Vaginal misoprostol (Dose less than 50 mcg) vs Vaginal misoprostol (Dose 50 mcg or more)	118	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias. No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Some or all funding from pharmaceutical industry
Kim 2000	Vaginal PGE2 (tablet) vs Vaginal misoprostol (Dose 50 mcg or more)	113	None with previous CS	Nulliparous only	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias. No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.

Kipikasaa 2005	Oral misoprostol tablet (Dose less than 50 mcg) vs Oral misoprostol tablet (dose 50mcg or more)	52	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All post-term	Singleton	Report describes allocation concealment. Low risk of bias.	One or both arms outpatient.	No pharmaceutical industry funding/ no conflicts of interest
Kolderup 1999	Intracervical PGE2 vs Vaginal misoprostol (Dose 50 mcg or more)	159	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Komala 2013	Vaginal misoprostol (Dose less than 50 mcg) vs Oral misoprostol tablet (dose 50mcg or more)	200	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	Not reported/ not clear	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Kovavisarach 1997	Vaginal PGE2 (tablet) vs Vaginal misoprostol (Dose 50 mcg or more)	60	Not reported/ not clear	Mixed parity	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Kovavisarach 1998	Vaginal PGE2 (tablet) vs Vaginal misoprostol (Dose 50 mcg or more)	80	Not reported/ not clear	Mixed parity	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Krithika 2008	Intracervical PGE2 vs Vaginal misoprostol (Dose less than 50 mcg)	100	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	Mixed (includes preterm)	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Kulshreshtha 2007	Intracervical PGE2 vs Vaginal misoprostol (Dose 50 mcg or more)	40	None with previous CS	Mixed parity	Mixed	Mixed	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Kumar 2001	Intracervical PGE2 vs Vaginal misoprostol (Dose less than 50 mcg)	200	None with previous CS	Mixed parity	Not reported/ not clear	Mixed	Mixed (includes preterm)	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Kwon 2001	Vaginal misoprostol (Dose 50 mcg or more) vs Oral misoprostol tablet (dose 50mcg or more)	160	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Langenegger 2005	Intracervical PGE2 vs Oral misoprostol tablet (dose 50mcg or more)	191	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.

Larmon 2002	Placebo vs Intracervical PGE2 vs Oestrogens	128	Not reported/ not clear	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	One or both arms outpatient.	Not reported/ not clear.
Laube 1986	Placebo vs Intracervical PGE2	45	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	Not reported/ not clear	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Some or all funding from pharmaceutical industry
Le Roux 2002	Vaginal PGE2 (gel) vs Vaginal misoprostol (Dose 50 mcg or more) vs Oral misoprostol tablet (dose 50mcg or more)	480	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Lee 1997	Vaginal PGE2 (tablet) vs Vaginal misoprostol (Dose 50 mcg or more)	50	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	All post-term	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Legarth 1988	Intracervical PGE2 vs Vaginal PGE2 pessary (normal release)	113	Not reported/ not clear	Mixed parity	Not reported/ not clear	All unfavourable (<6)	Not reported/ not clear	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Lemancewicz 1999	Intracervical PGE2 vs Vaginal misoprostol (Dose 50 mcg or more) vs IV oxytocin	131	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	All post-term	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Levy 2005	Placebo vs Oral misoprostol tablet (dose 50mcg or more)	130	None with previous CS	Mixed parity	All ruptured	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Lien 1998	Placebo vs Intracervical PGE2	93	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	All post-term	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Some or all funding from pharmaceutical industry
Liggins 1979	Placebo vs Vaginal PGE2 pessary (normal release)	84	Not reported/ not clear	Mixed parity	Not reported/ not clear	Mixed	All > 37 weeks	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	Some or all funding from pharmaceutical industry
Lo 2003	Placebo vs Oral misoprostol tablet (dose 50mcg or more)	102	None with previous CS	Nulliparous only	All ruptured	Not reported/ not clear	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Lokugamage 2003	Vaginal PGE2 (gel) vs Vaginal misoprostol (Dose 50 mcg or more)	191	None with previous CS	Nulliparous only	Mixed	All unfavourable (<6)	All > 37 weeks	Mixed	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Lopes 1991	Vaginal PGE2 (gel) vs Intracervical PGE2	50	Not reported/ not clear	Mixed parity	Mixed	All unfavourable (<6)	Not reported/ not clear	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.

Lopez-Farfan 2010	Vaginal PGE2 (pessary - slow release) vs Intracervical PGE2	50	Not reported/ not clear	Not reported/ not clear	All ruptured	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Lyndrup 1991	Intracervical PGE2 vs Vaginal PGE2 pessary (normal release)	125	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	Mixed (includes preterm)	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
MacKenzie 1979	Placebo vs Vaginal PGE2 (gel) vs PGF2 gel	48	None with previous CS	Nulliparous only	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
MacLennan 1979	Placebo vs PGF2 gel	80	None with previous CS	Mixed parity	Not reported/ not clear	Mixed	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Magtibay 1998	Intracervical PGE2 vs Vaginal misoprostol (Dose 50 mcg or more)	36	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Mahmood 1989	Vaginal PGE2 (tablet) vs Vaginal PGE2 (gel)	80	None with previous CS	Nulliparous only	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Mahmood 1992	No treatment vs Vaginal PGE2 (gel)	220	None with previous CS	Nulliparous only	All ruptured	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Mahmood 1995	No treatment vs Vaginal PGE2 (gel) Vaginal PGE2 pessary (normal release) vs Vaginal misoprostol (Dose 50 mcg or more) vs Titrated (low dose) oral misoprostol solution vs Extra-amniotic PGE2	100	None with previous CS	Multiparous only	All ruptured	All unfavourable (<6)	Not reported/ not clear	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Majoko 2002		406	None with previous CS	Mixed parity	Not reported/ not clear	Not reported/ not clear	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
McCaul 1997	No treatment vs Vaginal PGE2 (gel) vs IV oxytocin	91	None with previous CS	Mixed parity	All ruptured	All unfavourable (<6)	Mixed (includes preterm)	Mixed	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
McKenna 1999	Placebo vs Intracervical PGE2	61	Some with previous CS	Mixed parity	All intact	Mixed	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	One or both arms outpatient.	Not reported/ not clear.

McKenna 2004	Placebo vs Vaginal misoprostol (Dose less than 50 mcg)	68	None with previous CS	Mixed parity	All intact	Mixed	All post-term	Singleton	Report describes allocation concealment. Low risk of bias. No description of allocation concealment or unclear description. High risk of bias.	One or both arms outpatient.	Not reported/ not clear.
McLauren 1987	Vaginal PGE2 (tablet) vs Vaginal PGE2 (pessary - slow release)	24	Not reported/ not clear	Multiparous only	Not reported/ not clear	Mixed	All > 37 weeks	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Megalo 2004	Intracervical PGE2 vs Vaginal misoprostol (Dose 50 mcg or more)	200	None with previous CS	Mixed parity	Mixed	Mixed	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Mehrotra 2010	Vaginal misoprostol (Dose 50 mcg or more) vs Oral misoprostol tablet (dose 50mcg or more)	128	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Meydanli 2003	Vaginal misoprostol (Dose less than 50 mcg) vs Vaginal misoprostol (Dose 50 mcg or more)	120	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All post-term	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Meyer 2002	Intracervical PGE2 vs Vaginal misoprostol (Dose less than 50 mcg)	84	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	One or both arms outpatient.	Not reported/ not clear.
Miller 1991	Vaginal PGE2 (gel) vs Vaginal PGE2 (pessary - slow release)	40	Not reported/ not clear	Mixed parity	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Some or all funding from pharmaceutical industry
Moodley 2003	Vaginal PGE2 (gel) vs Vaginal misoprostol (Dose less than 50 mcg) vs Titrated (low dose) oral misoprostol solution	396	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Murphy 1980	Placebo vs PGF2 gel	265	Not reported/ not clear	Mixed parity	Not reported/ not clear	Mixed	All > 37 weeks	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	Some or all funding from pharmaceutical industry
Murray 1995	Vaginal PGE2 (tablet) vs Vaginal PGE2 (gel)	200	None with previous CS	Nulliparous only	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.

Murthy 2006	Intracervical PGE2 vs Vaginal misoprostol (Dose less than 50 mcg)	72	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias. No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Nager 1987	No treatment vs Intracervical PGE2	34	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Nagpal 2009	Intracervical PGE2 vs Oral misoprostol tablet (dose 50mcg or more)	61	None with previous CS	Mixed parity	All ruptured	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Nanda 2007	Intracervical PGE2 vs Vaginal misoprostol (Dose less than 50 mcg)	100	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Neiger 2001	Intracervical PGE2 vs Vaginal misoprostol (Dose 50 mcg or more)	61	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Neilson 1983	Vaginal PGE2 (gel) vs PGF2 gel	76	Not reported/ not clear	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Newman 1997	No treatment vs Vaginal PGE2 (gel)	58	Not reported/ not clear	Mixed parity	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	One or both arms outpatient.	Not reported/ not clear.
Ngai 1996	Placebo vs Oral misoprostol tablet (dose 50mcg or more)	80	None with previous CS	Mixed parity	All ruptured	Not reported/ not clear	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
NICHHD 1994	No treatment vs Placebo vs Intracervical PGE2	440	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All post-term	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Nigam 2010	Vaginal misoprostol (Dose less than 50 mcg) vs Vaginal misoprostol (Dose 50 mcg or more)	120	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Nimrod 1984	Placebo vs Intracervical PGE2	45	Not reported/ not clear	Not reported/ not clear	All intact	All unfavourable (<6)	Not reported/ not clear	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.

Noah 1987	No treatment vs Intracervical PGE2	816	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Some or all funding from pharmaceutical industry
Nopdonrattakoon 2003	Vaginal misoprostol (Dose 50 mcg or more) vs Oral misoprostol tablet (dose 50mcg or more)	106	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Nunes 1999	Vaginal PGE2 (gel) vs Vaginal misoprostol (Dose 50 mcg or more)	189	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias. Report describes allocation concealment.	Inpatient.	Not reported/ not clear.
Nuutila 1995	Placebo vs Intracervical PGE2	45	Not reported/ not clear	Mixed parity	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Nuutila 1996	Vaginal PGE2 (gel) vs Intracervical PGE2	110	Not reported/ not clear	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Oboro 2005	No treatment vs Vaginal misoprostol (Dose less than 50 mcg)	77	None with previous CS	Mixed parity	All intact	Mixed	All post-term	Singleton	Report describes allocation concealment. Low risk of bias.	One or both arms outpatient.	Not reported/ not clear.
O'Brien 1995	Placebo vs Vaginal PGE2 (gel)	100	Some with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	One or both arms outpatient.	No pharmaceutical industry funding/ no conflicts of interest
Ottinger 1998	Vaginal PGE2 (pessary - slow release) vs Intracervical PGE2	90	Some with previous CS	Mixed parity	All intact	Mixed	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Owen 1991	Placebo vs Intracervical PGE2	100	Not reported/ not clear	Mixed parity	All intact	All unfavourable (<6)	Not reported/ not clear	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Ozkan 2009	Vaginal PGE2 (pessary - slow release) vs Vaginal misoprostol (Dose 50 mcg or more)	112	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Paisarntantiwong 2005	Vaginal misoprostol (Dose less than 50 mcg) vs Oral misoprostol tablet (dose 50mcg or more)	146	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.

Pandis 2001	Vaginal PGE2 (gel) vs Vaginal misoprostol (Dose 50 mcg or more)	435	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias. No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Papanikolaou 2004	Vaginal PGE2 (tablet) vs Vaginal misoprostol (Dose 50 mcg or more)	163	None with previous CS	Nulliparous only	All intact	All unfavourable (<6)	All post-term	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Patil 2005	Intracervical PGE2 vs Oral misoprostol tablet (dose 50mcg or more)	190	Some with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Paungmora 2004	Vaginal misoprostol (Dose 50 mcg or more) vs Oral misoprostol tablet (dose 50mcg or more)	151	None with previous CS	Mixed parity	All intact	All unfavourable (<6)		Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Peccerillo 1995	Vaginal PGE2 (gel) vs Intracervical PGE2	67	Not reported/ not clear	Not reported/ not clear	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Pedrazzoli 1997	Vaginal PGE2 (gel) vs Intracervical PGE2	247	Not reported/ not clear	Not reported/ not clear	Not reported/ not clear	All unfavourable (<6)	Not reported/ not clear	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Perez Picanol 1990	No treatment vs Intracervical PGE2	71	Not reported/ not clear	Not reported/ not clear	All ruptured	All unfavourable (<6)	All > 37 weeks	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Perry 2004	Vaginal PGE2 (pessary - slow release) vs Intracervical PGE2	63	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Perryman 1992	Vaginal PGE2 (gel) vs Vaginal PGE2 pessary (normal release)	90	Not reported/ not clear	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Pongsatha 2005	Vaginal misoprostol (Dose 50 mcg or more) vs Oral misoprostol tablet (dose 50mcg or more)	166	None with previous CS	Not reported/ not clear	All intact	All unfavourable (<6)	Mixed (includes preterm)	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Poornima 2011	No treatment vs Vaginal PGE2 (gel)	100	Not reported/ not clear	Mixed parity	All ruptured	Mixed	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Poulsen 1991	Intracervical PGE2 vs Vaginal PGE2 pessary (normal release)	226	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.

Prager 2008	Vaginal PGE2 (gel) vs Vaginal misoprostol (Dose less than 50 mcg) vs Mechanical methods - foley catheter	588	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	All > 37 weeks	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Prasad 1989	Placebo vs Vaginal PGE2 (pessary - slow release)	69	None with previous CS	Nulliparous only	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Some or all funding from pharmaceutical industry
Prins 1983	Placebo vs Vaginal PGE2 (gel)	30	Not reported/ not clear	Not reported/ not clear	Not reported/ not clear	All unfavourable (<6)	Not reported/ not clear	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Puga 2001	Vaginal misoprostol (Dose 50 mcg or more) vs Oral misoprostol tablet (dose 50mcg or more)	270	None with previous CS	Not reported/ not clear	All ruptured	Not reported/ not clear	Mixed (includes preterm)	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Rabl 2002	Vaginal PGE2 (tablet) vs Vaginal PGE2 (pessary - slow release)	200	Some with previous CS	Mixed parity	Mixed	Mixed	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Rahman 2013	Vaginal misoprostol (Dose less than 50 mcg) vs Oral misoprostol tablet (dose 50mcg or more)	220	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Ramsey 2003	Vaginal PGE2 (pessary - slow release) vs Intracervical PGE2 vs Vaginal misoprostol (Dose 50 mcg or more)	111	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	Not reported/ not clear	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Rath 1999	Vaginal PGE2 (gel) vs Intracervical PGE2	468	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	All post-term	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Rath 1999	Vaginal PGE2 (tablet) vs Vaginal PGE2 (gel)	328	None with previous CS	Mixed parity	Mixed	All favourable (>6)	All post-term	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Rath 2007	No treatment vs Oral misoprostol tablet (dose 50mcg or more)	300	None with previous CS	Mixed parity	All ruptured	Not reported/ not clear	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.

Rayburn 1988	Placebo vs Vaginal PGE2 (gel)	118	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All post-term	Singleton	Report describes allocation concealment. Low risk of bias.	One or both arms outpatient.	Not reported/ not clear.
Rayburn 1992	Placebo vs Vaginal PGE2 (pessary - slow release)	215	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Some or all funding from pharmaceutical industry
Rayburn 1999	No treatment vs Intracervical PGE2	294	All with previous CS	Not reported/ not clear	All intact	All unfavourable (<6)	All > 37 weeks	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	One or both arms outpatient.	Some or all funding from pharmaceutical industry
Richardson 1991	Placebo vs Intracervical PGE2	48	Not reported/ not clear	Not reported/ not clear	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Rix 1996	Vaginal PGE2 (tablet) vs Intracervical PGE2	208	Not reported/ not clear	Mixed parity	Not reported/ not clear	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Rizvi 2007	Vaginal misoprostol (Dose less than 50 mcg) vs Oral misoprostol tablet (dose 50mcg or more)	59	None with previous CS	Mixed parity	All ruptured	All unfavourable (<6)	Mixed (includes preterm)	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Roach 1997	No treatment vs Vaginal PGE2 pessary (normal release)	201	Not reported/ not clear	Mixed parity	Not reported/ not clear	Not reported/ not clear	All post-term	Singleton	Report describes allocation concealment. Low risk of bias.	One or both arms outpatient.	Not reported/ not clear.
Rouzi 2014	Vaginal PGE2 (pessary - slow release) vs Titrated (low dose) oral misoprostol solution	160	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Rowlands 2001	Vaginal PGE2 pessary (normal release) vs Vaginal misoprostol (Dose 50 mcg or more)	125	None with previous CS	Nulliparous only	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	One or both arms outpatient.	Not reported/ not clear.

Rozenberg 2001	Vaginal PGE2 (gel) vs Vaginal misoprostol (Dose 50 mcg or more)	369	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Rozenberg 2004	Vaginal PGE2 (pessary - slow release) vs Vaginal misoprostol (Dose 50 mcg or more)	140	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Saeed 2011	Vaginal PGE2 (tablet) vs Vaginal misoprostol (Dose 50 mcg or more)	200	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Saggaf 2001	Vaginal PGE2 (gel) vs Vaginal misoprostol (Dose 50 mcg or more)	57	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Sahraoui 2005	No treatment vs Intracervical PGE2	150	Not reported/ not clear	Mixed parity	All intact	All unfavourable (<6)	All post-term	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	One or both arms outpatient.	Not reported/ not clear.
Sahu 2004	Intracervical PGE2 vs Vaginal misoprostol (Dose 50 mcg or more)	50	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Saleem 2006	Vaginal PGE2 pessary (normal release) vs Vaginal misoprostol (Dose 50 mcg or more) vs Mechanical methods - foley catheter	226	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Sanchez-Ramos 1998	Vaginal PGE2 (pessary - slow release) vs Vaginal misoprostol (Dose 50 mcg or more)	223	None with previous CS	Mixed parity	Mixed	Mixed	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Sawai 1991	Placebo vs Vaginal PGE2 (gel)	50	None with previous CS	Mixed parity	All intact	Mixed	All post-term	Singleton	Report describes allocation concealment. Low risk of bias.	One or both arms outpatient.	Not reported/ not clear.
Sawai 1994	Placebo vs Vaginal PGE2 pessary (normal release)	80	None with previous CS	Mixed parity	All intact	Mixed	All post-term	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	One or both arms outpatient.	Not reported/ not clear.

Saxena 2011	Intracervical PGE2 vs Vaginal misoprostol (Dose less than 50 mcg) vs Vaginal misoprostol (Dose 50 mcg or more)	210	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Schneider 2004	Vaginal misoprostol (Dose less than 50 mcg) vs Oral misoprostol tablet (dose 50mcg or more)	296	Not reported/ not clear	Not reported/ not clear	Not reported/ not clear	Not reported/ not clear	Not reported/ not clear	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Seeras 1995	Vaginal PGE2 (gel) vs Intracervical PGE2	68	None with previous CS	Mixed parity	All intact	Not reported/ not clear	All > 37 weeks	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Shakya 2010	Intracervical PGE2 vs Vaginal misoprostol (Dose 50 mcg or more) vs Intracervical PGE2 vs Vaginal misoprostol (Dose less than 50 mcg) vs Oral misoprostol tablet (dose 50mcg or more)	66	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Sheela 2007	Vaginal misoprostol (Dose less than 50 mcg) vs Oral misoprostol tablet (dose 50mcg or more) vs Mechanical methods - foley catheter	150	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Sheikher 2009	Mechanical methods - foley catheter	90	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Shetty 2001	Vaginal misoprostol (Dose 50 mcg or more) vs Oral misoprostol tablet (dose 50mcg or more)	245	None with previous CS	Mixed parity	Not reported/ not clear	Mixed	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Shetty 2002 a	No treatment vs Oral misoprostol tablet (dose 50mcg or more)	61	None with previous CS	Mixed parity	All ruptured	Not reported/ not clear	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Shetty 2003	Vaginal misoprostol (Dose less than 50 mcg) vs Oral misoprostol tablet (dose 50mcg or more)	101	None with previous CS	Mixed parity	All intact	Mixed	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Shetty 2004	Vaginal PGE2 (tablet) vs Oral misoprostol tablet (dose 50mcg or more)	200	None with previous CS	Mixed parity	All intact	Mixed	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Shoaib 1994	No treatment vs Vaginal PGE2 (tablet)	200	None with previous CS	Nulliparous only	All ruptured	All unfavourable (<6)	All > 37 weeks	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.

Sifakis 2007	Vaginal PGE2 (tablet) vs Vaginal misoprostol (Dose 50 mcg or more)	415	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Sitthiwattanawong 1999	Vaginal misoprostol (Dose 50 mcg or more) vs Oral misoprostol tablet (dose 50mcg or more)	131	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	Mixed (includes preterm)	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Smith 1990	Vaginal PGE2 (gel) vs Vaginal PGE2 pessary (normal release)	69	Not reported/ not clear	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Smith 1994	Vaginal PGE2 (gel) vs Vaginal PGE2 (pessary - slow release)	121	Not reported/ not clear	Not reported/ not clear	All intact	All unfavourable (<6)	All > 37 weeks	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Souza 2013	Vaginal misoprostol (Dose less than 50 mcg) vs Titrated (low dose) oral misoprostol solution	200	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Srisomboon 1996	Placebo vs Vaginal misoprostol (Dose 50 mcg or more)	62	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Stampe Sorensen 1992	Vaginal PGE2 (tablet) vs Vaginal PGE2 pessary (normal release)	267	Not reported/ not clear	Mixed parity	Not reported/ not clear	Mixed	Mixed (includes preterm)	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Stempel 1997	Vaginal PGE2 (gel) vs Intracervical PGE2	83	Not reported/ not clear	Mixed parity	Not reported/ not clear	All unfavourable (<6)	Not reported/ not clear	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Steytler 1995	Vaginal PGE2 (gel) vs Vaginal misoprostol (Dose 50 mcg or more)	30	None with previous CS	Not reported/ not clear	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Stitely 2000	Placebo vs Vaginal misoprostol (Dose less than 50 mcg)	60	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All post-term	Singleton	Report describes allocation concealment. Low risk of bias.	One or both arms outpatient.	No pharmaceutical industry funding/ no conflicts of interest

Strobel 2006	Vaginal PGE2 (pessary - slow release) vs Intracervical PGE2	107	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Sultana 2006	Vaginal misoprostol (Dose 50 mcg or more) vs Oral misoprostol tablet (dose 50mcg or more)	100	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Surbek 1997	Vaginal PGE2 (tablet) vs Vaginal misoprostol (Dose 50 mcg or more)	100	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Tabor 1995	Intracervical PGE2 vs Vaginal misoprostol (Dose 50 mcg or more)	127	Not reported/ not clear	Not reported/ not clear	Not reported/ not clear	All unfavourable (<6)	Not reported/ not clear	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Taechakraichana 1996	Intracervical PGE2 vs Vaginal PGE2 pessary (normal release)	19	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	Not reported/ not clear	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Taher 2010	Vaginal PGE2 (tablet) vs Vaginal PGE2 (gel)	165	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	All > 37 weeks	Mixed	Report describes allocation concealment. Low risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Tan 2010	Vaginal PGE2 pessary (normal release) vs Vaginal misoprostol (Dose less than 50 mcg)	169	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Tessier 1997	Vaginal PGE2 (gel) vs Oral misoprostol tablet (dose 50mcg or more)	267	Some with previous CS	Mixed parity	Mixed	Mixed	Mixed (includes preterm)	Mixed	Report describes allocation concealment. Low risk of bias.	One or both arms outpatient.	Not reported/ not clear.
Tey 1995	No treatment vs Intracervical PGE2	40	Not reported/ not clear	Not reported/ not clear	Not reported/ not clear	Mixed	All > 37 weeks	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.

Thaisomboon 2012	Oral misoprostol tablet (dose 50mcg or more) vs Titrated (low dose) oral misoprostol solution	64	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All post-term	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Thavarahsah 1990	Vaginal PGE2 (tablet) vs Intracervical PGE2	200	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Thiery 1984	Placebo vs Vaginal PGE2 (tablet) vs Intracervical PGE2	121	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Thomas 2000	Placebo vs Vaginal misoprostol (Dose 50 mcg or more)	52	Not reported/ not clear	Mixed parity	All ruptured	Not reported/ not clear	Mixed (includes preterm)	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Tomlinson 2001	Vaginal PGE2 (gel) vs Vaginal PGE2 (pessary - slow release)	69	None with previous CS	Mixed parity	All intact	Mixed	Mixed (includes preterm)	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Topozada 1997	Vaginal misoprostol (Dose 50 mcg or more) vs Oral misoprostol tablet (dose 50mcg or more)	40	Not reported/ not clear	Mixed parity	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Trabelsi 2012	Intracervical PGE2 vs Vaginal misoprostol (Dose 50 mcg or more)	300	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	Mixed (includes preterm)	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Triglia 2010	Vaginal PGE2 (gel) vs Vaginal PGE2 (pessary - slow release)	130	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Trofatter 1985	Placebo vs Intracervical PGE2	59	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Some or all funding from pharmaceutical industry
Trofatter 1993	No treatment vs Intracervical PGE2	488	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Mixed	Report describes allocation concealment. Low risk of bias.	Inpatient.	Some or all funding from pharmaceutical industry
Troostwijk 1992	Placebo vs Intracervical PGE2	139	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Some or all funding from pharmaceutical industry

Ulmsten 1983	Placebo vs Intracervical PGE2	50	None with previous CS	Nulliparous only	Not reported/ not clear	Not reported/ not clear	All > 37 weeks	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Ulmsten 1985	Placebo vs Intracervical PGE2 vs Vaginal PGE2 pessary (normal release)	58	Not reported/ not clear	Nulliparous only	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Uludag 2005	Vaginal misoprostol (Dose 50 mcg or more) vs Oral misoprostol tablet (dose 50mcg or more)	99	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	Mixed (includes preterm)	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Van Germund 2004	Vaginal PGE2 (gel) vs Vaginal misoprostol (Dose less than 50 mcg)	681	Some with previous CS	Mixed parity	Mixed	All unfavourable (<6)	Mixed (includes preterm)	Mixed	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Varaklis 1995	Intracervical PGE2 vs Vaginal misoprostol (Dose less than 50 mcg)	69	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Some or all funding from pharmaceutical industry
Wang 1998	Vaginal misoprostol (Dose less than 50 mcg) vs Vaginal misoprostol (Dose 50 mcg or more)	48	Not reported/ not clear	Not reported/ not clear	All intact	Not reported/ not clear	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Not reported/ not clear.	Not reported/ not clear.
Wieland 1999	Vaginal PGE2 (pessary - slow release) vs Intracervical PGE2	66	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Not reported/ not clear	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Wielgos 2007	Vaginal PGE2 (pessary - slow release) vs Intracervical PGE2	128	Not reported/ not clear	Mixed parity	Not reported/ not clear	All unfavourable (<6)	Mixed (includes preterm)	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Wing 1995 a	Intracervical PGE2 vs Vaginal misoprostol (Dose 50 mcg or more)	135	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Wing 1995 b	Intracervical PGE2 vs Vaginal misoprostol (Dose less than 50 mcg)	275	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Wing 1997	Vaginal PGE2 (pessary - slow release) vs Vaginal misoprostol (Dose less than 50 mcg)	197	None with previous CS	Not reported/ not clear	All intact	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Wing 1999	Vaginal misoprostol (Dose less than 50 mcg) vs Oral misoprostol tablet (dose 50mcg or more)	220	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.

Wing 2000	Vaginal misoprostol (Dose less than 50 mcg) vs Oral misoprostol tablet (dose 50mcg or more)	234	None with previous CS	Mixed parity	Mixed	Mixed	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Wing 2008	Vaginal PGE2 (pessary - slow release) vs Sustained release misoprostol insert	1307	None with previous CS	Mixed parity	Mixed	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Wing 2013	Vaginal PGE2 (pessary - slow release) vs Sustained release misoprostol insert	1358	None with previous CS	Mixed parity	Not reported/ not clear	All unfavourable (<6)	Mixed (includes preterm)	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Some or all funding from pharmaceutical industry
Witter 1992	Placebo vs Vaginal PGE2 (pessary - slow release)	72	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Some or all funding from pharmaceutical industry
Witter 1996	Placebo vs Vaginal PGE2 (pessary - slow release)	206	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Some or all funding from pharmaceutical industry
Yazdani 2012	Placebo vs Oral misoprostol tablet (dose 50mcg or more)	99	Not reported/ not clear	Not reported/ not clear	All ruptured	Not reported/ not clear	All > 37 weeks	Not reported/ not clear	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Yuen 1996	Intracervical PGE2 vs Vaginal PGE2 pessary (normal release) vs Mechanical methods - Double balloon or Cook's catheter	119	Some with previous CS	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.
Zanconato 2011	Vaginal PGE2 (gel) vs Vaginal PGE2 (pessary - slow release)	52	None with previous CS	Nulliparous only	All intact	All unfavourable (<6)	All > 37 weeks	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	No pharmaceutical industry funding/ no conflicts of interest
Zanini 1990	Vaginal PGE2 (gel) vs Intracervical PGE2	100	None with previous CS	Mixed parity	All intact	All unfavourable (<6)	Mixed (includes preterm)	Singleton	No description of allocation concealment or unclear description. High risk of bias.	Inpatient.	Not reported/ not clear.
Zvandasara 2008	Vaginal misoprostol (Dose 50 mcg or more) vs Titrated (low dose) oral misoprostol solution	134	None with previous CS	Mixed parity	Mixed	Not reported/ not clear	Mixed (includes preterm)	Singleton	Report describes allocation concealment. Low risk of bias.	Inpatient.	Not reported/ not clear.

